Assay for ubiquitin ligase activity: High-throughput screen for inhibitors of HDM2

Journal of Biomolecular Screening

Volumn 9, Issue 8, 2004, Pages 695-703

  Davydov, I V ^a   Woods, D ^b,c   Safiran, Y J ^a   Oberoi, P ^a   Fearnhead, H O ^b   Fang, S ^b,d   Jensen, J P ^b   Weissman, A M ^b   Kenten, J H ^a   Vousden, K H ^b,e  

^a Meso Scale Discovery   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Human Genome Science ^*  (United States)

^d UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

^e BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

E3; HDM2; Mdm2; p53; Ubiquitin

Indexed keywords

ENZYME INHIBITOR; PROTEIN HDM2 INHIBITOR; PROTEIN MDM2; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E3 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; AUTOUBIQUITINATION; DRUG IDENTIFICATION; DRUG SCREENING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; PRIORITY JOURNAL; PROTEIN DOMAIN; UBIQUITINATION;

ANIMALS; BIOLOGICAL ASSAY; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; MICE; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SPECTROMETRY, FLUORESCENCE; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

EID: 20144389192     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087057104267956     Document Type: Article

References (34)

1. Schwarte DC, Hochstrasser M: A superfamily of protein tags: ubiquitin, SUMO and related modifiers. Trends Biochem Sci 2003;28:321-328.
2. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373-428.
3. Yang Y, Yu X: Regulation of apoptosis: the ubiquitous way. FASEB J 2003;17:790-799.
4. Clarke DJ: Proteolysis and the cell cycle. Cell Cycle 2002;1:233-234.
5. Nalepa G, Wade Harper J: Therapeutic anti-cancer targets upstream of the proteasome. Cancer Treat Rev 2003;29(suppl. 1):49-57.
6. Fang S, Lorick KL, Jensen JP, Weissman AM: RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin Cancer Biol 2003;13:5-14.
7. Pickart CM: Mechanisms underlying ubiquitination. Ann Rev Biochem 2001;70:503-533.
8. Hicke L: Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2001;2:195-201.
9. Jackson PK, Eldridge AG, Freed E, et al: The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 2000;10:429-439.
10. Adams J: Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003;8:307-315.
11. Vousden KH: Activation of the p53 tumor suppressor gene. Biochem Biophys Acta 2002;1602:47-59.
12. Chen L, Agrawal S, Zhou W, Zhang R, Chen J: Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 1998;95:195-200.
13. Zhang Z, Li M, Wang H, Agrawal S, Zhang R: Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 2003;100:11636-11641.
14. Chen L, Lu W, Agrawal S, Zhou W, Zhang R, Chen J: Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol Med 1999;5:21-34.
15. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM: Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000;275:8945-8951.
16. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 1999;18:22-27.
17. Midgley CA, Desterro JM, Saville MK, et al: An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 2000;19:2312-2323.
18. Zhang Y, Wolf GW, Bhat K, et al: Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 2003;23:8902-8912.
19. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998;17:5001-5014.
20. Lohrum MA, Ludwig RL, Kubbutat MHG, Hanlon M, Vousden KH: Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003;3:577-587.
21. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-723.
22. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MR Sherr CJ: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998;95:8292-8297.
23. Jensen JP, Bates PW, Yang M, Vierstra RD, Weissman AM: Identification of a family of closely related human ubiquitin conjugating enzymes. J Biol Chem 1995;270:30408-30414.
24. Hatakeyama S, Jensen JP, Weissman AM: Subcellular localization and ubiquitin-conjugating enzyme (E2) interactions of mammalian HECT family ubiquitin protein ligases. J Biol Chem 1997;272:15085-15092.
25. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000;288:874-877.
26. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM: RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 1999;96:11364-11369.
27. Honda R, Tanaka H, Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-27.
28. Sharp DA, Kratowicz SA, Sank MJ, George DL: Stabilization of the MDM2 oncogene by interaction with the structurally related MDMX protein. J Biol Chem 1999;274:38189-38196.
29. Badciong JC, Haas AL: MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J Biol Chem 2002;277:49668-49675.
30. Jackson MW, Berberich SJ: MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol 2000;20:1001-1007.
31. Stad R, Ramos YF, Little N, et al: HdmX stabilizes Mdm2 and p53. J Biol Chem 2000;275:28039-28044.
32. Meulmeester E, Frenk R, Stad R, et al: Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Biol Cell 2003;23:4929-4938.
33. Fabbro D, Garcia-Echeverria C: Targeting protein kinases in cancer therapy. Curr Opin Drug Discov Dev 2002;5:701-712.
34. Lai Z, Yang T, Kim YB, et al: Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci USA 2002;99:14734-14739.